Drug Pricing

More than a dozen semaglutide generics hit the Indian market at sharp discounts post LOE for Novo Nordisk’s GLP-1 RA molecule, setting the stage for a high-octane battle in the diabetes and obesity segment. Can Novo hold steady amid the avalanche and what are KOLs looking for?

Speaking to Generics Bulletin on the sidelines of the AAM’s Access! 2026 conference, IGBA chair for 2026 Jim Keon – also president of the CGPA and Biosimilars Canada – discussed IP abuses, supply challenges, biosimilar streamlining and the importance of giving the off-patent industry a global voice.

A Senate report finds GSK’s withdrawal of Flovent and shift to an authorized generic increased costs, restricted access and disrupted asthma care, while helping the company avoid Medicaid rebates, raising broader concerns over pricing loopholes.

Centrient has urged the EU to strengthen its supply chain resilience, including incentivizing local manufacturing through revised procurement practices, after India took action to protect its antibiotics market from an increasing Chinese monopoly.

As India implements minimum import prices for certain antibiotics and key starting materials, Sandoz's Simon Goeller speaks to Generics Bulletin about the potential for Chinese suppliers to dominate the world market and weaponize supply.

Samsung Bioepis’ Ospomyv and Celltrion’s Stoboclo will be preferred on major US commercial formularies from April 2026, as CVS Caremark drops Prolia and another higher-cost brand, Forteo (teriparatide), to drive savings.

After taking the reins as president of Medicines for Europe at the start of 2026, Zentiva CEO Steffen Saltofte sets out priorities for the group that include ensuring access to medicines, industry resilience and competitiveness, harmonized regulation, and sustainability for the off-patent sector.

With another settlement secured, US states are gearing up for the first trial of the price-fixing case later this year.

The health technology assessment institute said its recommendation for the multiple sclerosis drugs, Tysabri and Tyruko, highlighted its continued efforts to drive the adoption of biosimilars across the National Health Service.

As more medicines come off patent in the coming years, the UK generics and biosimilars industry association is hoping to see more generic products evaluated for reimbursement by the health technology assessment institute, NICE.

Sandoz’s CEO used the firm’s latest results call to highlight “trade distortion” in the pencillins market as a result of US tariffs, urging European authorities to take action to reduce the region’s “geopolitical exposure” and safeguard the long-term sustainability of European-produced penicillins.

Companies have been given two extra weeks to decide whether they want to leave the UK’s voluntary pricing scheme for branded medicines, adding to a previous four-week deadline extension.

The AAM has asked for a federal injunction to block a Connecticut state law on drug pricing that it says represents “an unconstitutional overreach that threatens patient access to affordable medicines.”

Through an expansion of their partnership, Biocon Biologics and Civica Rx are planning to launch a private-label version of insulin glargine in the US from January – at a price that equates to just $11 per pen.

While branded generics and biosimilars remain subject to the UK’s VPAG pricing scheme, Sandoz’s public affairs lead has argued that focusing on driving competition and uptake rather than rebates is a better way to generate savings – and that off-patent products should be exempt from VPAG altogether.

The AAM and Biosimilars Forum have criticized a rule adopted by Colorado’s Prescription Drug Affordability Board to establish an upper payment limit for Enbrel – well ahead of market entry for etanercept biosimilars.

The European generics industry has welcomed news that generic medicines will be exempt from tariffs under the latest EU-US trade agreement.

The AAM has welcomed a US appeals court decision backing an injunction against a Minnesota state law on drug pricing, following an earlier favorable district court ruling.

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.